Mylan NV will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.
Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.
Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.
Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.
Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.
Celgene Corp. exceeded expectations for second-quarter 2016 earnings on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines.
Eli Lilly reported better-than-expected second-quarter 2016 sales and predicted average annual revenue growth of at least 5 percent through the end of the decade.
Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.
Roche beat market expectations for adjusted net income in the first-half 2016, helped by cancer drug sales but also inflated by a one-off gain from its pensions scheme.